Coherus Oncology (CHRS) Intangibles (2014 - 2026)

Coherus Oncology has disclosed Intangibles across 13 years of filings, most recently posting $26.2 million for Q2 2026.

• In Q2 2026, Intangibles fell 9.08% year-over-year to $26.2 million; the TTM figure through Jun 2026 stood at $26.2 million (down 9.08% YoY), while the FY2025 annual figure was $26.2 million, down 9.08% from the prior year.
• Intangibles came in at $26.2 million for Q2 2026 at Coherus Oncology, roughly flat from $26.2 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $41.9 million in Q4 2023 to a low of $5.9 million in Q4 2022.
• Average Intangibles over 5 years is $27.5 million, with a median of $28.9 million recorded in 2023.
• Year-over-year, Intangibles jumped 605.97% in 2023 and slumped 31.08% in 2024.
• Over 5 years, Intangibles stood at $5.9 million in 2022, then jumped by 605.97% to $41.9 million in 2023, then tumbled by 31.08% to $28.9 million in 2024, then declined by 9.08% to $26.2 million in 2025, then changed by 0.0% to $26.2 million in 2026.
• Per Business Quant data, the three most recent Intangibles figures were $26.2 million in Q2 2026, $26.2 million in Q1 2026, and $26.2 million in Q4 2025.